Session » Metabolic & Crystal Arthropathies – Basic & Clinical Science Poster II

Date: Sunday, November 17, 2024

Time: 10:30AM-12:30PM

Meeting: ACR Convergence 2024

10:30AM-12:30PM: Abstract Number: 1097

CERT Score as a Potential Tool to Predict Cardiovascular Risk in Gout and Hyperuricemia

10:30AM-12:30PM: Abstract Number: 1092

Chronic Kidney Disease Is Associated with Increased Glucose Uptake-associated Metabolic Activity of Visceral Adipose and Subcutaneous Adipose Tissue in Gout Patients

10:30AM-12:30PM: Abstract Number: 1083

Comparison of a Handheld Ultrasound Device with Cart-Based Ultrasound for the Assessment of Gout Lesions in People with Established Gout

10:30AM-12:30PM: Abstract Number: 1100

Coronary Dual-Energy Computed Tomography for the Detection of Monosodium Urate Crystal Deposition in the Arteries of Individuals with and Without Gout (CORODECT): A Multi-Center Prospective Imaging Study

10:30AM-12:30PM: Abstract Number: 1099

Distinct Metabolomic Signatures of Insulinemia and Incident Gout Risk: A Prospective Cohort Study Among Women

10:30AM-12:30PM: Abstract Number: 1089

Endothelial Activation in Gout

10:30AM-12:30PM: Abstract Number: 1096

Exploring Multi Factorial Model for the Prediction of Gout in Patients with Hyperuricemia

10:30AM-12:30PM: Abstract Number: 1090

Hepatic Fibrosis Before and During Intensive Urate-lowering with Pegloticase in the Presence and Absence of Methotrexate Co-therapy

10:30AM-12:30PM: Abstract Number: 1094

Longitudinal Analysis of Serum Urate in Prediabetic Phase

10:30AM-12:30PM: Abstract Number: 1091

Mapping Monosodium Urate Crystal Deposition Within Joints in Tophaceous Gout: A Dual Energy CT Study

10:30AM-12:30PM: Abstract Number: 1084

Osteoporosis and Osteopenia Diagnosed by Dual-Energy X-Ray Absorptiometry Are Not Increased in Patients with Gout

10:30AM-12:30PM: Abstract Number: 1085

Pharmacokinetics and Pharmacodynamics of Tigulixostat in Participants with Mild, Moderate, and Severe Renal Impairment

10:30AM-12:30PM: Abstract Number: 1098

Prognostic Value of Hyperuricemia in Developing Cardiovascular Events in Patients with Chronic Inflammatory Arthritis: A 10-Year Prospective Study

10:30AM-12:30PM: Abstract Number: 1088

Prospective Evaluation of Carotid Atherosclerosis, Urate Deposits and Inflammation After One Year of Treatment in Newly Diagnosed Gout

10:30AM-12:30PM: Abstract Number: 1086

Risk Factors Associated with Loss to Follow-up in a Prospective Gout Cohort

10:30AM-12:30PM: Abstract Number: 1093

Risk of Dementia in Patients with Gout: Potential Impact of Survival Bias

10:30AM-12:30PM: Abstract Number: 1102

Risk of Mortality and Major Cardiovascular-Kidney Outcomes in Patients with Tophaceous versus Non-Tophaceous Gout

10:30AM-12:30PM: Abstract Number: 1087

Sex Differences in Clinical Features and Mortality in Gout: A Nationwide Retrospective Cohort Study

10:30AM-12:30PM: Abstract Number: 1101

The Contemporary Prevalence of Comorbid Gout and Chronic Kidney Disease, Two Common Conditions with High Morbidity, in the US General Population

10:30AM-12:30PM: Abstract Number: 1095

The Incidence of Gout Among Individuals with Hyperuricemia over Time – an Insight from a Nationwide Cohort Study

10:30AM-12:30PM: Abstract Number: 1103

The Role of Renal Dual-Energy CT in Exploring the Gouty Kidney: The RENODECT Study

« View all sessions from this meeting

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].